Literature DB >> 8496332

Modulation of the steroidogenesis of cultured human granulosa-lutein cells by gonadotropin-releasing hormone analogs.

I Bussenot1, C Azoulay-Barjonet, J Parinaud.   

Abstract

GnRH analogs are widely used in reproductive medicine to create a hypogonadotropic hypogonadism. However, numerous animal studies have demonstrated a direct regulation of the gonadal function by GnRH. To ascertain this direct ovarian effect in humans, the steroidogenesis of cultured human granulosa cells was studied with or without GnRH and five of its agonists. Buserelin (D-Ser(But)6, desGly10) GnRH ethylamide, leuprorelin (D-Leu6, desGly10) GnRH ethylamide, H4055 (desGly10) GnRH ethylamide, and H4065 (D-Trp6, desGly10) GnRH ethylamide significantly enhanced estradiol secretion. In addition, buserelin induced a significant cell surface decrease that seemed to be mediated by cytoskeleton modifications. The two other molecules, GnRH and triptorelin (D-Trp6) GnRH), had no effect on estrogen secretion at any of the studied concentrations. Thus, despite similar pituitary effects, these agonists did not exhibit the same ovarian action. This may be accounted for by the differences found between pituitary and ovarian receptors. These results suggest that some GnRH analogs can modulate human granulosa cell steroidogenesis at least in the preovulatory period.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8496332     DOI: 10.1210/jcem.76.5.8496332

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  7 in total

1.  Effects of human follicular fluid and high-density lipoproteins on early spermatozoa hyperactivation and cholesterol efflux.

Authors:  Safouane M Hamdi; Gérard Vieitez; Béatrice Jaspard; Ronald Barbaras; Bertrand Perret; Roget Mieusset; Jean Parinaud; Xavier Collet
Journal:  J Lipid Res       Date:  2009-11-30       Impact factor: 5.922

2.  The effect of leuprorelin on steroidogenesis of human preovulatory granulosa cells in vitro.

Authors:  R Fabbri; E Porcu; A Pession; E Sereni; T Marsella; R Seracchioli; C Flamigni
Journal:  J Assist Reprod Genet       Date:  1996-04       Impact factor: 3.412

3.  Ovarian hyper-response to administration of an GnRH-agonist without gonadotropins.

Authors:  Hyun Tae Park; Hyo Sook Bae; Tak Kim; Sun Haeng Kim
Journal:  J Korean Med Sci       Date:  2011-10-01       Impact factor: 2.153

Review 4.  Depot versus daily administration of gonadotrophin-releasing hormone agonist protocols for pituitary down regulation in assisted reproduction cycles.

Authors:  Luiz Eduardo T Albuquerque; Leopoldo O Tso; Humberto Saconato; Maria Cecília R M Albuquerque; Cristiane R Macedo
Journal:  Cochrane Database Syst Rev       Date:  2013-01-31

5.  The effects of gonadotropin-releasing hormone agonist on androstenedione production and follicular development during controlled ovarian hyperstimulation.

Authors:  K Akaboshi; T Oda; J Yoshida; S Kohriyama; T Miyazaki; Y Yoshimura
Journal:  J Assist Reprod Genet       Date:  1998-09       Impact factor: 3.412

6.  Effect of in vivo GnRH agonist and GnRH antagonist on hCG and insulin-stimulated progesterone production by human granulosa-lutein cells in vitro.

Authors:  Mohamed F M Mitwally; Robert F Casper
Journal:  J Assist Reprod Genet       Date:  2002-08       Impact factor: 3.412

Review 7.  Leuprorelin. A review of its pharmacology and therapeutic use in prostatic cancer, endometriosis and other sex hormone-related disorders.

Authors:  G L Plosker; R N Brogden
Journal:  Drugs       Date:  1994-12       Impact factor: 9.546

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.